Loading...

Diane Marie Da Silva, PhD, MS

Title(s)Assistant Professor of Research Obstetrics & Gynecology
Phone+1 323 442 3868
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Da Silva's current research interests span multiple areas of study that include applying immune modulation strategies to enhance natural and vaccine-induced immunity against solid tumors, investigating the molecular and cellular determinants in the tumor microenvironment that lead to cancer development, progression and metastasis, and assessing the clinical significance of the cervico-vaginal microbiota in relation to gynecologic cancer development, progression and response to treatment.

    Dr. Da Silva has broad expertise and skills associated with immunology, oncology and infectious disease research, immunotherapeutics, vaccine immunogenicity and efficacy, pre-clinical vaccine/adjuvant development, small animal syngeneic and xenograft tumor models, clinical translational research, and analysis of immune responses and biomarkers in human clinical samples for many different types of cancer. Dr. Da Silva is the Technical Director of the Norris Comprehensive Cancer Center Beckman Center for Immune Monitoring, a core resource for collecting, processing and analyzing human clinical trial samples to discover and validate immune-related biomarkers of response to cancer therapies. She has spent the past 15 years studying human papillomavirus (HPV) interactions with host immune cell receptors and immune escape mechanisms used by HPV, and has been involved with development of therapeutic vaccine strategies against HPV-induced cancers.

    Since 2015, Dr. Da Silva is the course director for the undergraduate Introductory course in Modern Oncology and Cancer Biology for the USC Minor in Health Care Studies.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2019 Nov 27. PMID: 31774464.
      View in: PubMed
    2. Da Silva DM, Skeate JG, Chavez-Juan E, Lühen KP, Wu JM, Wu CM, Kast WM, Hwang K. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine. 2019 May 16; 37(22):2915-2924. PMID: 31010714.
      View in: PubMed
    3. Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. BMC Cancer. 2018 Oct 11; 18(1):970. PMID: 30309325.
      View in: PubMed
    4. Rodrigues LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, Oliveira NS, Chavez-Juan E, Da Silva DM, Kast WM, Nicol AF, Pilotto JH. Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors. Gynecol Oncol. 2018 10; 151(1):102-110. PMID: 30087059.
      View in: PubMed
    5. Taylor JR, Fernandez DJ, Thornton SM, Skeate JG, Lühen KP, Da Silva DM, Langen R, Kast WM. Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation. Sci Rep. 2018 08 03; 8(1):11642. PMID: 30076379.
      View in: PubMed
    6. Woodham AW, Cheloha RW, Ling J, Rashidian M, Kolifrath SC, Mesyngier M, Duarte JN, Bader JM, Skeate JG, Da Silva DM, Kast WM, Ploegh HL. Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res. 2018 07; 6(7):870-880. PMID: 29792298.
      View in: PubMed
    7. Skeate JG, Da Silva DM, Chavez-Juan E, Anand S, Nuccitelli R, Kast WM. Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS One. 2018; 13(1):e0191311. PMID: 29324830.
      View in: PubMed
    8. Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HH, Wong MK, Da Silva DM, Kast WM. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res. 2016 12; 2:21-30. PMID: 27182559.
      View in: PubMed
    9. Woodham AW, Sanna AM, Taylor JR, Skeate JG, Da Silva DM, Dekker LV, Kast WM. Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 11 18; 13(1):187. PMID: 27863502.
      View in: PubMed
    10. Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna-Andrade C, Oliveira NS, Woodham AW, DA Silva DM, Kast WM. Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. J Acquir Immune Defic Syndr. 2016 09 01; 73(1):27-33. PMID: 27149102.
      View in: PubMed
    11. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 07; 30(7):291-306. PMID: 27410493.
      View in: PubMed
    12. Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. PMID: 26835746.
      View in: PubMed
    13. Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res. 2016 05; 36(5):291-301. PMID: 26653678.
      View in: PubMed
    14. Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015 Dec 01; 1:12-21. PMID: 26665182.
      View in: PubMed
    15. Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva DM, Yuan W, Martin Kast W. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol. 2016 Feb; 97(2):422-434. PMID: 26555393.
      View in: PubMed
    16. Da Silva DM, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LI, Roman LD, Yessaian AA, Pham HQ, Matsuo K, Lin YG, McKee GM, Salazar AM, Kast WM. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol. 2015 Dec; 161(2):197-208. PMID: 26360252.
      View in: PubMed
    17. Bogaert L, Woodham AW, Da Silva DM, Martens A, Meyer E, Kast WM. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol. 2015 Sep; 96(9):2764-8. PMID: 26044793.
      View in: PubMed
    18. Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, Kast WM. Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother. 2015; 70(6):1686-90. PMID: 25712315.
      View in: PubMed
    19. Yan L, Da Silva DM, Verma B, Gray A, Brand HE, Skeate JG, Porras TB, Kanodia S, Kast WM. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015 Feb 15; 75(3):280-91. PMID: 25399517.
      View in: PubMed
    20. Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014 May 15; 192(10):4748-57. PMID: 24719459.
      View in: PubMed
    21. Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM. Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype. Virology. 2014 Mar; 452-453:279-86. PMID: 24606705.
      View in: PubMed
    22. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013 Jun; 87(11):6062-72. PMID: 23536685.
      View in: PubMed
    23. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One. 2012; 7(8):e43519. PMID: 22927980.
      View in: PubMed
    24. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 2010 May 15; 70(10):3955-64. PMID: 20460520.
      View in: PubMed
    25. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. PMID: 19918923.
      View in: PubMed
    26. Fahey LM, Raff AB, Da Silva DM, Kast WM. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009 Nov 15; 183(10):6151-6. PMID: 19864613.
      View in: PubMed
    27. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. PMID: 19789304.
      View in: PubMed
    28. Fahey LM, Raff AB, Da Silva DM, Kast WM. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009 Mar 01; 182(5):2919-28. PMID: 19234187.
      View in: PubMed
    29. Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008 Apr 24; 8:8. PMID: 18433090.
      View in: PubMed
    30. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2):247-59. PMID: 17973257.
      View in: PubMed
    31. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15; 178(12):7587-97. PMID: 17548594.
      View in: PubMed
    32. Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM, Storkus WJ. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol. 2005 Jul; 66(7):762-72. PMID: 16112023.
      View in: PubMed
    33. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005 Jun 01; 174(11):7172-8. PMID: 15905561.
      View in: PubMed
    34. Fausch SC, Da Silva DM, Kast WM. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005 Feb 25; 23(14):1720-9. PMID: 15705478.
      View in: PubMed
    35. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003 Jul 01; 63(13):3478-82. PMID: 12839929.
      View in: PubMed
    36. Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003; 16(2):111-21. PMID: 12828864.
      View in: PubMed
    37. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002 Sep 15; 169(6):3242-9. PMID: 12218143.
      View in: PubMed
    38. Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology. 2002; 45(4-6):300-7. PMID: 12566713.
      View in: PubMed
    39. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology. 2001 Nov 25; 290(2):350-60. PMID: 11883199.
      View in: PubMed
    40. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001 May 15; 166(10):5917-24. PMID: 11342606.
      View in: PubMed
    41. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol. 2001 May; 13(5):633-41. PMID: 11312251.
      View in: PubMed
    42. Small LA, Da Silva DM, de Visser KE, Velders MP, Fisher SG, Potkul RK, Kast WM. A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. PMID: 11300486.
      View in: PubMed
    43. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, Kast WM. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol. 2001 Feb; 186(2):169-82. PMID: 11169454.
      View in: PubMed
    44. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Müller M, Kast WM. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem. 1999 May 01; 73(2):145-52. PMID: 10227378.
      View in: PubMed
    45. Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Müller M, Greenstone HL, Schiller JT, Kast WM. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem. 1999 Mar; 380(3):335-40. PMID: 10223336.
      View in: PubMed
    46. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM. Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. PMID: 11249689.
      View in: PubMed